0.01 (9.09%) 1d
Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4. The company thinks there are opportunities in Colombia as well. These markets are 6 times larger than in Canada.

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
They have low level light therapy. They were recognized about two months ago for mucusitis treatment and its prevention. They also make equipment to detect melanoma.

They have a new President and CEO. They released a new web site. They replace needles for dental work with laser. On the innovative side, their Durham product gives totally secure examination of a mole with results in 72 hours. The long awaited approval of the devices in Mexico is expected soon. There are expected global partnerships. He thinks there are really good opportunities for them.


He thinks there is good opportunity for this medical device manufacturer with the arrival of a new CEO. Note: His wife works as a consultant for this company.


This company sells technology that looks with light 2 mm below the skin to determine whether you have melanoma, moles or otherwise. Skin cancer is a growing problem and this is a good product for it. The company is gaining customers in Spanish-speaking countries (Spain, Mexico, etc.)


This company's product is truly revolutionary, because it looks millimetres below the skin’s surface to actually see what is going on. They take a picture, send it on a secure basis to a dermatologist, who then sees the situation. A year ago, they retooled their laser therapy device, and that is selling quite well. They are working on some improved software to make it easier on a "plug-and-play" basis for the actual melanoma detection device. A great product. The company needs sales of about $1.8 million to break even, and they have $9 million of tax loss carry forward. His expectation is that by Q3 of 2018, they will be profitable. He owns warrants on this.


Their numbers were up 13%. They have a device that looks at moles for Melanoma. They are now focusing on health and safety for workers. There is a pilot going on with Loblaw’s.

Showing 1 to 7 of 7 entries
  • «
  • 1
  • »

Medx Health Corp.(MDX-X) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Medx Health Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Medx Health Corp.(MDX-X) Frequently Asked Questions

What is Medx Health Corp. stock symbol?

Medx Health Corp. is a Canadian stock, trading under the symbol MDX-X on the TSX Venture Exchange (MDX-CV). It is usually referred to as TSXV:MDX or MDX-X

Is Medx Health Corp. a buy or a sell?

In the last year, there was no coverage of Medx Health Corp. published on Stockchase.

Is Medx Health Corp. a good investment or a top pick?

Medx Health Corp. was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Medx Health Corp..

Why is Medx Health Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Medx Health Corp. worth watching?

0 stock analysts on Stockchase covered Medx Health Corp. In the last year. It is a trending stock that is worth watching.

What is Medx Health Corp. stock price?

On 2022-11-22, Medx Health Corp. (MDX-X) stock closed at a price of $0.05.